ClinicalTrials.Veeva

Menu

A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms (RAPID-III)

R

Rivermark Medical

Status

Enrolling

Conditions

Benign Prostatic Hyperplasia

Treatments

Device: Sham (Control)
Device: FloStent

Study type

Interventional

Funder types

Industry

Identifiers

NCT06849258
C0002 Rev. 07

Details and patient eligibility

About

The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.

Enrollment

215 estimated patients

Sex

Male

Ages

45+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male subjects > 45 years of age who have symptomatic BPH
  • International Prostate Symptom Score (IPSS) score >13
  • Peak urinary flow rate (Qmax): >5 mL/sec and <13 mL/sec with minimum voided volume of >125 mL
  • Post-void residual (PVR) <250 mL
  • Prostate volume 25 to 80 mL
  • Prostatic urethral length 20-50 mm
  • Able to complete the study protocol and visits

Exclusion criteria

  • Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
  • Prior minimally invasive intervention or surgical intervention of the prostate or urethra
  • PSA >10 ng/mL
  • Bladder cancer or bladder stones
  • Active urinary tract infection (UTI)
  • Uncontrolled diabetes
  • Part of a vulnerable population (cognitively challenged or are incarcerated)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

215 participants in 2 patient groups

Treatment - FloStent
Experimental group
Description:
Flexible cystoscopy procedure with FloStent implant deployed
Treatment:
Device: FloStent
Sham Control
Sham Comparator group
Description:
Flexible cystoscopy procedure without FloStent implant deployed
Treatment:
Device: Sham (Control)

Trial contacts and locations

20

Loading...

Central trial contact

Study Manager Study Director, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems